48
Participants
Start Date
July 23, 2018
Primary Completion Date
December 1, 2022
Study Completion Date
December 1, 2022
Venetoclax
tablet, oral
Dinaciclib
intravenous
Monash Medical Centre /ID# 202762, Melbourne
Gold coast University Hospital /ID# 202759, Southport
Royal Hobart Hospital /ID# 202763, Hobart
Hospital Universitario Ramon y Cajal /ID# 201729, Madrid
Hospital Universitario de Salamanca /ID# 201728, Salamanca
The Ohio State University /ID# 200668, Columbus
Hospital Universitario y Politecnico La Fe /ID# 202318, Valencia
The University ofChicago /ID# 200017, Chicago
University of Arkansas /ID# 200016, Little Rock
University of Texas MD Anderson Cancer Center /ID# 205215, Houston
David Geffen School of Medicin /ID# 200015, Los Angeles
University of Maryland School of Medicine /ID# 204015, Baltimore
Wake Forest Baptist Medical Center /ID# 200288, Winston-Salem
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
AbbVie
INDUSTRY